Rosyrah NDC 70700-312

NDC codes

FDA NDC Directory

Product NDC (as listed)70700-312Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70700-0312Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70700-312-87	70700031287	1 POUCH in 1 CARTON (70700-312-87) / 1 BLISTER PACK in 1 POUCH / 1 KIT in 1 BLISTER PACKMarketed from Jan 29, 2025

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rosyrah
Generic name (nonproprietary): levonorgestrel and ethinyl estradiol and ethinyl estradiol
Dosage form: Kit
Route: Oral
Labeler: Xiromed, LLC
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 206053
Marketing start: Jan 29, 2025
Listing expires: Dec 31, 2027
Identifiers: Product ID 70700-312_4fb6f740-69bf-590d-4474-43ff5c2e5986SPL ID 4fb6f740-69bf-590d-4474-43ff5c2e5986SPL set ID d2f0af55-205f-df9c-c572-1f7b14976655RxCUI 238019, 248310, 1373501, 1373502, 1373503, 2705814UPC 0370700312872

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470700031287 followed by a unit qualifier and the quantity

Package 70700-0312-87. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Nov 10, 2025. This label includes a boxed warning.

Indications (excerpt from the label)

Rosyrah is a combination of levonorgestrel, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Rosyrah is indicated for use by females of reproductive age to prevent pregnancy.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 206053

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 206053
Product	Strength	Form · route	Labeler	Product NDC
Levonorgestrel And Ethinyl Estradiol And Ethinyl Estradiol	—	Kit	Mylan Pharmaceuticals Inc.	0378-7316